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Nuclear HMGB1 that contains 3 cysteine residues is acetylated and secreted to the extracellular space,
promoting inﬂammation via multiple molecules such as RAGE and TLR4. We thus evaluated and char-
acterized the redox state-dependent effects of peripheral HMGB1 on nociception. Intraplantar (i.pl.)
administration of bovine thymus-derived HMGB1 (bt-HMGB1), all-thiol HMGB1 (at-HMGB1) or disulﬁde
HMGB1 (ds-HMGB1) caused long-lasting mechanical hyperalgesia in mice. The hyperalgesia following
i.pl. bt-HMGB1 or at-HMGB1 was attenuated by RAGE inhibitors, while the ds-HMGB1-induced hyper-
algesia was abolished by a TLR4 antagonist. Thus, nociceptive processing by peripheral HMGB1 is
considered dependent on its redox states.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).High mobility group box 1 (HMGB1), a DNA binding protein, is
passively released from necrotic cells and actively secreted by
certain cells such as macrophages, playing a pro-inﬂammatory role
as damage-associated molecular patterns (DAMPs) (1). In macro-
phages, nuclear HMGB1 is acetylated by histone acetyltransferases
(HATs) and deacetylated by histone deacetylases (HDACs), and the
acetylated HMGB1 is translocated to the cytoplasm and then
packaged to secretory lysosomes, followed by its active secretion to
the extracellular space (2). The extracellular HMGB1 targets mul-
tiple molecules including Toll-like receptor 4 (TLR4), TLR2 and the
receptor for advanced glycation endproducts (RAGE), and also
forms a heterocomplex with two CXC chemokine ligand 12
(CXCL12) molecules which accelerates the activation of CXC-
chemokine receptor 4 (CXCR4) through the receptor dimerization,
playing a pro-inﬂammatory role (3). HMGB1 contains 3 cysteine
residues, C23, C45 and C106, and the redox modiﬁcation of themgy and Pathophysiology, Fac-
e, Higashi-Osaka 577-8502,
wabata).
rmacological Society.
. Production and hosting by Elseaffects the potency of HMGB1 in activating distinct receptors; all-
thiol-HMGB1 (at-HMGB1) is capable of activating RAGE and also
CXCL12/CXCR4 signals, while disulﬁde-HMGB1 (ds-HMGB1) that
has an intramolecular disulﬁde bond between C23 and C45
preferentially interacts with TLR4 (3e5). Intracellular HMGB1 is
present in the all-thiol form and released to the extracellular space,
and the released at-HMGB1 may be oxidized to ds-HMGB1 by
reactive oxygen species (ROS) during inﬂammation (3). There is
plenty of evidence for the pro-nociceptive role of HMGB1 in the
spinal cord or dorsal root ganglion (DRG) (5,6). Recent independent
studies have shown that intrathecal administration of ds-HMGB1,
but not at-HMGB1, causes hyperalgesia in mice (6,7), while at-
HMGB1 and ds-HMGB1 cause excitation of acutely dissociated rat
DRG neurons via activation of RAGE and TLR4, respectively (5). On
the other hand, we have reported that peripheral HMGB1 plays a
pro-nociceptive role in somatic inﬂammatory hyperalgesia (8) and
also in cystitis-related bladder pain/referred hyperalgesia (9),
whereas the redox state-dependence of peripheral HMGB1-
induced hyperalgesia remains unclear. Thus, we examined and
characterized the effects of peripheral HMGB1 in distinct redox
states on somatic nociception in mice.
Male ddY mice (3 weeks old) were purchased from Kiwa Lab-
oratory Animals Co., Ltd (Wakayama, Japan) and housed in a roomvier B.V. This is an open access article under the CC BY-NC-ND license (http://
D. Yamasoba et al. / Journal of Pharmacological Sciences 130 (2016) 139e142140kept at 22e24 C under a 12-h day/night cycle with free access to
food and water at least for 1 week before experiments. All animals
were used with approval by the Committee for the Care and Use of
Laboratory Animals at Kindai University, and all procedures
employed in the present study were in accordance with the
guidelines of the Committee for Research and Ethical Issues of IASP
[www.iasp-pain.org/Education/Content.aspx?ItemNumber¼1217].
Bovine thymus-derived HMGB1 (bt-HMGB1) was purchased from
Shino-Test Corp. (Tokyo, Japan), and recombinant all-thiol-HMGB1
(at-HMGB1) and disulﬁde-HMGB1 (ds-HMGB1) were from
HMGBiotech (Milan, Italy). Trichostatin A (TSA), suberoylanilideFig. 1. The mechanical hyperalgesia following intraplantar administration of bovine th
administration of bovine thymus-derived HMGB1 (bt-HMGB1) at 1e1000 ng/paw (A, D, FeI
The anti-HMGB1 neutralizing antibody or the control IgG at 1 mg/kg (D, E), LMWH, known to
at 5 mg/kg (I) was administered i.p. 30 min before i.pl. bt-HMGB1 at 100 ng/paw and before
IgG at 100 ng/paw was administered i.pl. 1 h before i.pl. bt-HMGB1 at 100 ng/paw (G). Data s
curve between 1.5 and 3 h after challenge with bt-HMGB1 or HDAC inhibitors. The number
*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (V) (AeC) or V þ V (DeI); yP < 0.05, yyP < 0.hydroxamic acid (SAHA) and AMD3100 were purchased from
SigmaeAldrich (St. Louis, MO, USA), and lipopolysaccharide from
Rhodobacter sphaeroides (LPS-RS) was from InvivoGen (San Diego,
CA, USA). Low molecular weight heparin (LMWH) was a gift from
Fuso Pharmaceutical Industries, Ltd. (Osaka, Japan). TSA and
SAHA were dissolved in DMSO and then diluted with saline (the
ﬁnal DMSO concentration was 0.3%), and all other chemicals were
dissolved in saline. An anti-human HMGB1 neutralizing rat
monoclonal antibody and the control IgG were produced by Dr.
Nishibori (Okayama University Graduate School of Medicine,
Okayama, Japan), and dissolved in 0.01 M phosphate-bufferedymus-derived HMGB1 or HDAC inhibitors in mice. Mice received intraplantar (i.pl.)
) or of TSA and SAHA, HDAC inhibitors, 3 or 30 pmol/paw (B, C, E) in a volume of 10 ml.
inhibit RAGE, at 2.5 mg/kg (F), LPS-RS, a TLR4 antagonist, at 0.5 mg/kg (H) or AMD3100
i.pl. TSA or SAHA at 30 pmol/paw. The anti-RAGE neutralizing antibody or the control
how the mean ± SEM of the nociceptive threshold or of the AUC of the timeethreshold
of mice: 4e6 (A), 5e10 (B), 6e12 (C), 5 (D), 7e9 (E), 5e9 (F), 6e8 (G), 6e7 (H) and 4 (I).
01 vs. IgG þ bt-HMGB1 (D, G), V þ TSA or SAHA (E), and V þ bt-HMGB1 (F, H, I).
D. Yamasoba et al. / Journal of Pharmacological Sciences 130 (2016) 139e142 141saline (PBS). The anti-rat RAGE rabbit polyclonal antibody and the
control rabbit IgG were obtained from SigmaeAldrich and Cell
Signaling Technology (Danvers, MA, USA), respectively, and dis-
solved in 0.1 M PBS. In the von Frey test, the mice were placed and
acclimatized on a risenwire mesh ﬂoor, covered with a clear plastic
box (10  10  10 cm), and the mid-plantar surface of the rightFig. 2. The mechanical hyperalgesia caused by intraplantar administration of all-thiol-H
(at-HMGB1) (A, C, D) or disulﬁde-HMGB1 (ds-HMGB1) (B, E, F) at 1e100 ng/paw in a volume
at 0.5 mg/kg (D, F) was administered i.p. 30 min before i.pl. HMGB1. Data show the mean ± S
and 3 h after HMGB1 challenge. The number of mice: 5e8 (A), 5e7 (B), 5e9 (C), 5e8 (D), 4e6
yP < 0.05, yyP < 0.01 vs. V þ at-HMGB1 (C) or V þ ds-HMGB1 (F).hindpaw was stimulated with von Frey ﬁlaments of distinct
strength (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 0.6 and 1.0 g). The noci-
ceptive threshold was determined according to the up-down
method (10). In some experiments, the area under the curve
(AUC) was calculated from the timeethreshold curve between 1.5
and 3 h after intraplantar (i.pl.) injection of test compounds. DataMGB1 or disulﬁde-HMGB1 in mice.Mice received intraplantar (i.pl.) all-thiol-HMGB1
of 10 ml. LMWH, known to inhibit RAGE, at 2.5 mg/kg (C, E) or LPS-RS, a TLR4 antagonist,
EM of the nociceptive threshold or of the AUC of the timeethreshold curve between 1.5
(E), and 4e6 (F). *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle (V) (A, B) or V þ V (CeF);
D. Yamasoba et al. / Journal of Pharmacological Sciences 130 (2016) 139e142142are shown as mean ± S.E.M. Non-parametric analyses were per-
formed by ManneWhitney's U-test for comparison of two-group
data and by KruskaleWallis H-test followed by a least signiﬁcant
difference-type test for comparison of three or more group data.
Intraplantar injection of bt-HMGB1 caused long-lasting hyper-
algesia in a dose rage of 100e1000 ng/paw (Fig. 1A), as seen in our
previous study using rats (8). Given evidence that decreased HDAC
activity promotes the acetylation, cytosolic translocation and
extracellular release of HMGB1 (11), we asked if HDAC inhibitors
produce pro-nociceptive activity. TSA and SAHA, distinct HDAC
inhibitors, when administered i.pl. at 3e30 pmol/paw, mimicked
the long-lasting hyperalgesia (Fig. 1B, C), as caused by i.pl. bt-
HMGB1 (Fig. 1A). Systemic (i.p.) administration of the anti-
HMGB1 neutralizing antibody at 1 mg/kg abolished the hyper-
algesia induced by i.pl. bt-HMGB1 at 100 ng/paw (Fig. 1D), and
partially prevented the hyperalgesia following i.pl. TSA or SAHA at
30 pmol/paw (Fig. 1E). The hyperalgesia caused by i.pl. bt-HMGB1
was partially but signiﬁcantly inhibited by i.p. administration of
LMWH at 2.5 mg/kg, known to directly block RAGE (12), and by i.pl.
administration of the anti-RAGE neutralizing antibody at 100 ng/
paw (Fig. 1F, G). In contrast, the bt-HMGB1-induced hyperalgesia
was only slightly attenuated by i.p. LPS-RS, a TLR4 antagonist, at
0.5 mg/kg and unaffected by i.p. AMD3100, a CXCR4 antagonist, at
5 mg/kg (Fig. 1H, I). As did bt-HMGB1, i.pl. administration of re-
combinant at-HMGB1 or ds-HMGB1 produced long-lasting hyper-
algesia (Fig. 2A, B). The effective dose range of at-HMGB1 was
100 ng/paw or more (Fig. 2A), equivalent to bt-HMGB1 (see Fig. 1A),
while that of ds-HMGB1 was 10e100 ng/paw (Fig. 2B), much more
potent than at-HMGB1 (see Fig. 2A) and bt-HMGB1 (see Fig. 1A).
The hyperalgesia caused by i.pl. at-HMGB1 was partially inhibited
by i.p. LMWH (Fig. 2C), but not by i.p. LPS-RS (Fig. 2D), being similar
to the characteristics of the bt-HMGB1-induced hyperalgesia (see
Fig. 1F, H). In contrast, the i.pl. ds-HMGB1-induced hyperalgesia
was abolished by i.p. LPS-RS (Fig. 2F), but resistant to i.p. LMWH
(Fig. 2E).
Our data demonstrate that peripheral at-HMGB1 promotes
mechanical nociception at least in part through activation of RAGE,
but not TLR4, while peripheral ds-HMGB1 produces more potent
pro-nociceptive activity exclusively via activation of TLR4, but not
RAGE. Considering that the anti-HMGB1 neutralizing antibody
partially blocked the hyperalgesia induced by i.pl. HDAC inhibitors
(see Fig. 1E), it is hypothesized that the accelerated acetylation and
secretion of endogenous HMGB1 following HDAC inhibition might
contribute, at least in part, to promotion of nociceptive processing.
In general, HDAC inhibition is considered analgesic, whereas there
is evidence that the epigenetic modulation by HDAC inhibition
restores nerve injury-induced down-regulation of Nav1.8 channels
and subsensitivity of C-ﬁber neurons (13). Thus, the possibility
cannot be ruled out that the epigenetic modulation of unknown
pro-nociceptive molecules by HDAC inhibition is involved in the
HMGB1-independent portion of the hyperalgesic effect of HDAC
inhibitors. The bt-HMGB1 is considered almost in the all-thiol form,
since the potency and characteristics of the pro-nociceptive activity
of bt-HMGB1 were similar to the recombinant at-HMGB1. The
ﬁnding that LPS-RS slightly reduced the hyperalgesia induced by
bt-HMGB1 or at-HMGB1 (see Figs. 1H and 2D), suggests that a small
amount of bt-HMGB1/at-HMGB1, administered i.pl., might be
oxidized to ds-HMGB1 in the tissue. It is necessary to test whether
the hyperalgesia induced by i.pl. ds-HMGB1 or at-HMGB1 involves
the direct or indirect activation of TLR2, another target for ds-
HMGB1, since TLR2 may also play a pro-nociceptive role (14). The
pro-nociceptive role of CXCR4 has been reported elsewhere (15),whereas it does not appear to contribute to the bt-HMGB1-induced
hyperalgesia (see Fig.1I). This ﬁndingmay be in agreement with the
report that at-HMGB1 is incapable of activating CXCR4 unless
forming a heterocomplex with CXCL12 (3).
In conclusion, our study demonstrates that both at-HMGB1 and
ds-HMGB in the peripheral tissue are capable of causing mechan-
ical hyperalgesia via activation of RAGE and TLR4, respectively, in
mice, and that the latter is more potent than the former as a
nociceptive promoter. Thus, the pro-nociceptive property for pe-
ripheral HMGB1 are considered dependent on its redox-state.Conﬂict of interest
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